{"groups":[{"description":"once-time routine surgery with (either of CO2 laser at continue model and 10.0-20.0 W, or \"cold\" surgery with micro-instruments), in 15 subjects","id":"FG000","title":"Control"},{"description":"once-time PDL surgery at 6.0-8.0 W, followed by oral taking of Celecoxib (100mg,BID)for 9 months","id":"FG001","title":"Experimental"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"3"}],"type":"Lost to Follow-up"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"8"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"5"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"3"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Many patients, who were eligible for this study, finally declined to participate this study due to a safety concern with Celebrex","recruitmentDetails":"3 years"}